Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00410605 · FLOW

Participant flow

Bevacizumab, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Stage II or III Multiple Myeloma · Source last updated 2017-09-01

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15, oral lenalidomide on days 1-21, and oral dexamethasone on days 1, 8, 15, and 22. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. bevacizumab: Given IV lenalidomide: Given orally dexamethasone: Given orally
    id
    FG000
    title
    Bevacizumab, Dexamethasone, and Lenalidomide
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        12
      type
      Adverse Event
    2. reasons
      1. group Id
        FG000
        num Subjects
        3
      type
      Physician Decision
    3. reasons
      1. group Id
        FG000
        num Subjects
        5
      type
      Withdrawal by Subject
    4. reasons
      1. group Id
        FG000
        num Subjects
        3
      type
      Started Non-Protocol Therapy
    5. reasons
      1. group Id
        FG000
        num Subjects
        1
      type
      Stopped treatmen to collect stem cells
    6. reasons
      1. group Id
        FG000
        num Subjects
        1
      type
      Transferred to another Institution
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        39
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        14
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        25
      type
      NOT COMPLETED
    title
    Overall Study
pre Assignment Details
No events between enrollment and group assignment. All subjects enrolled are immediately assigned to Arm 1, "Bevacizumab, Dexamethasone, and Lenalidomide."
recruitment Details
Participants were recruited from the University of Wisconsin (UW) Hospital and Clinics, the UW 1 South Park Clinic, and the Wisconsin Oncology Network (WON) clinics between November 2006 and March 2011.
Complete source fields
groups
  1. description
    Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15, oral lenalidomide on days 1-21, and oral dexamethasone on days 1, 8, 15, and 22. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. bevacizumab: Given IV lenalidomide: Given orally dexamethasone: Given orally
    id
    FG000
    title
    Bevacizumab, Dexamethasone, and Lenalidomide
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        12
      type
      Adverse Event
    2. reasons
      1. group Id
        FG000
        num Subjects
        3
      type
      Physician Decision
    3. reasons
      1. group Id
        FG000
        num Subjects
        5
      type
      Withdrawal by Subject
    4. reasons
      1. group Id
        FG000
        num Subjects
        3
      type
      Started Non-Protocol Therapy
    5. reasons
      1. group Id
        FG000
        num Subjects
        1
      type
      Stopped treatmen to collect stem cells
    6. reasons
      1. group Id
        FG000
        num Subjects
        1
      type
      Transferred to another Institution
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        39
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        14
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        25
      type
      NOT COMPLETED
    title
    Overall Study
pre Assignment Details
No events between enrollment and group assignment. All subjects enrolled are immediately assigned to Arm 1, "Bevacizumab, Dexamethasone, and Lenalidomide."
recruitment Details
Participants were recruited from the University of Wisconsin (UW) Hospital and Clinics, the UW 1 South Park Clinic, and the Wisconsin Oncology Network (WON) clinics between November 2006 and March 2011.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice